FDA OKs New Treatment for Advanced or Metastatic HER2-Positive Breast Cancer
April 17th 2020Officials with the FDA today approved tucatinib (Tukysa, Seattle Genetics) in combination with chemotherapy trastuzumab and capecitabine for the treatment of adults with advanced forms of HER2-positive breast cancer.
A Conversation About Cancer Care During COVID-19: Part 2
April 14th 2020In part 2 of our video interview, Robert Brunault, PharmD, a clinical pharmacy specialist in hematology and oncology at Rhode Island Hospital and the Lifespan Cancer Institute, discussed drug shortages, FDA emergency use authorizations, and the biggest concerns for pharmacists.